{"id":37413,"date":"2025-07-16T15:06:49","date_gmt":"2025-07-16T07:06:49","guid":{"rendered":"https:\/\/flcube.com\/?p=37413"},"modified":"2025-07-16T15:06:50","modified_gmt":"2025-07-16T07:06:50","slug":"otsuka-to-acquire-cantargias-il-1rap-monoclonal-antibody-can10-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37413","title":{"rendered":"Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases"},"content":{"rendered":"\n

Japan-based drug maker Otsuka (OTCMKTS: OTSKY<\/a>) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka’s portfolio in autoimmune disease therapies.<\/p>\n\n\n\n

Acquisition Details<\/strong>
Otsuka gains global exclusive rights for the development, manufacturing, and commercialization of CAN10 and related assets. Financial terms include an upfront payment of USD 33 million to Cantargia, with additional milestone payments committed as the development progresses.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB…<\/p>\n","protected":false},"author":1,"featured_media":37415,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4224,2246,439],"class_list":["post-37413","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cantargia","tag-otcmkts-otsky","tag-otsuka-pharmaceutical"],"yoast_head":"\nOtsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka's portfolio in autoimmune disease therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37413\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka's portfolio in autoimmune disease therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37413\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T07:06:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-16T07:06:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases\",\"datePublished\":\"2025-07-16T07:06:49+00:00\",\"dateModified\":\"2025-07-16T07:06:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413\"},\"wordCount\":100,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1601.webp\",\"keywords\":[\"Cantargia\",\"OTCMKTS: OTSKY\",\"Otsuka Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37413#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37413\",\"name\":\"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1601.webp\",\"datePublished\":\"2025-07-16T07:06:49+00:00\",\"dateModified\":\"2025-07-16T07:06:50+00:00\",\"description\":\"Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka's portfolio in autoimmune disease therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37413\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37413#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry","description":"Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka's portfolio in autoimmune disease therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37413","og_locale":"en_US","og_type":"article","og_title":"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases","og_description":"Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka's portfolio in autoimmune disease therapies.","og_url":"https:\/\/flcube.com\/?p=37413","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-16T07:06:49+00:00","article_modified_time":"2025-07-16T07:06:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37413#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37413"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases","datePublished":"2025-07-16T07:06:49+00:00","dateModified":"2025-07-16T07:06:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37413"},"wordCount":100,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37413#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp","keywords":["Cantargia","OTCMKTS: OTSKY","Otsuka Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37413#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37413","url":"https:\/\/flcube.com\/?p=37413","name":"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37413#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37413#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp","datePublished":"2025-07-16T07:06:49+00:00","dateModified":"2025-07-16T07:06:50+00:00","description":"Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB all assets related to CAN10, an IL-1RAP-targeting monoclonal antibody (mAb) under development for the treatment of autoimmune diseases. This strategic move expands Otsuka's portfolio in autoimmune disease therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37413#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37413"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37413#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp","width":1080,"height":608,"caption":"Otsuka to Acquire Cantargia's IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37413#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37413"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37413\/revisions"}],"predecessor-version":[{"id":37416,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37413\/revisions\/37416"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37415"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}